Zenas BioPharma eyes 2026 commercial launch following Phase 3 obexelimab success
Zenas BioPharma (NASDAQ:ZBIO) announced its full-year 2025 financial results on March 16, 2026, marking a pivotal year that has positioned the Waltham, Massachusetts-based biotech for its first potential product launch.

_1360536_640x360_2492235331860-640x360.webp&w=1200&q=75)



-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













